Jane Street
LYEL icon

Jane Street’s Lyell Immunopharma LYEL Stock Holding History

Jane Street’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-505
Closed -$35K – 9543
2022
Q4 		$35K Buy
+505
New +$50.2K ﹤0.01% 8467

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street's LYEL Position: Q1 2026 in Review

Jane Street increased its Lyell Immunopharma (LYEL) stake by 415% in Q1 2026, buying an estimated $1.2M and bringing the position to 63,893 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #5969.

Jane Street first reported a position in LYEL in Q3 2021 and has held it in 15 quarters since. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Jane Street held 63,893 shares of Lyell Immunopharma worth $1.28M as of Q1 2026.
  • Jane Street bought 51,484 Lyell Immunopharma shares in Q1 2026, an estimated $1.2M.
  • Lyell Immunopharma made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5969 holding.
  • Jane Street first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 15 quarters since.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.